Companies › Renibus Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Veverimer Patented resin-based medication that buffers acid in the gastrointestinal tract | – | Phase 3 | CKD | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07355062 | Veverimer | Phase 3 | CKD | Metabolic and endocrine | Jun 2027 |
No annotated target.
–
Fresenius Kabi Chendu DIAO Pharmaceutical Group Kowa Company Azafaros Waterstone Pharmaceutical (Wuhan)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.